Telormedix’ TMX-101 Commences Clinical Trial for Bladder Cancer
The trial will be a Phase I/II, open-label, multicenter, dose escalation study which will consist of three parts. In the first part of the study, the safety and maximum tolerated dose (MTD) will be tested in patients with non-muscle-invasive bladder cancer (NMIBC) who have undergone a complete transurethral resection (TUR). TMX-101 will be administered once a week for a total of six instillations into the bladder of patients who have undergone TUR. The second part of the study will be an assessment of the effective biological dose in patients with one marker lesion remaining after TUR. Finally, the third part of the study will follow each of the patients to assess the safety of TMX-101 and the status of the disease within the first year. The study will be conducted in the Netherlands at four investigational sites and Telormedix anticipates that there will be a total of 21 to 30 patients.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.